Akèy › Karsinòm selil skuamèz tèt ak kou › North Carolina › Charlotte
Etid klinik pou Karsinòm selil skuamèz tèt ak kou nan Charlotte, NC
10 etid pou Karsinòm selil skuamèz tèt ak kou ap chèche patisipan nan sit nan ak bò kote Charlotte (nan yon distans apeprè 30 mil). Louvri yon etid pou wè ki moun ki ka patisipe ak kijan pou kontakte ekip etid la.
Tèks ofisyèl etid la (Anglè)
Ap chèche patisipan pou yon etid? Mete l anwo paj sa a — $99 pou 30 jou →
Anti-Ly6E Exatecan ADC M7437 in Advanced Solid Tumors
Ap rekriteFaz 1
- Carolina BioOncology Institute, LLC - Cancer Therapy and Research Center, Huntersville · 13 mi lwen
JNJ-90301900 (NBTXR3) Activated by Radiotherapy With or Without Cetuximab in LA-HNSCC
Ap rekriteFaz 3
- Atrium Health Levine Cancer Institute, Charlotte
Study of AU-007, A Monoclonal Antibody That Binds to IL-2 and Inhibits IL-2Rα Binding, in Patients With Unresectable Locally Advanced or Metastatic Cancer
Ap rekriteFaz 1/2
- Carolina Biooncology Institute, Huntersville · 13 mi lwen
A Study to Assess the Adverse Events, Change in Disease Activity, and How Oral ABBV-711 Tablets Move Through the Body as a Monotherapy and in Combination With Intravenously Infused Budigalimab (ABBV-181), in Adults With Advanced Squamous Tumors
Ap rekriteFaz 1
- Carolina BioOncology Institute /ID# 272380, Huntersville · 13 mi lwen
Testing the Addition of the Drug BMX-001, a Radioprotector, or a Placebo to the Usual Chemoradiation Therapy for Patients With Head and Neck Cancer
Ap rekriteFaz 2
- Carolinas Medical Center/Levine Cancer Institute, Charlotte
- Atrium Health Pineville/LCI-Pineville, Charlotte
- Atrium Health University City/LCI-University, Charlotte
- ak 5 plis
Phase 1/2 Study of ETX-636 in Participants With Advanced Solid Tumors
Ap rekriteFaz 1/2
- Carolina BioOncology Institute, Huntersville · 13 mi lwen
Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma and Other Solid Tumors, Receiving Intravenous Infusion of Azirkitug Alone or in Combination(s) With Budigalimab, Bevacizumab, or Telisotuzumab Adizutecan
Ap rekriteFaz 1
- Carolina BioOncology Institute /ID# 232597, Huntersville · 13 mi lwen
Study of CP-383 in Patients With Advanced or Metastatic Solid Tumors
Ap rekriteFaz 1/2
- Carolina BioOncology Institute, Huntersville · 13 mi lwen
A Study of DR-0202 in Patients With Locally Advanced or Metastatic, Relapsed or Refractory Carcinomas
Ap rekriteFaz 1
- Dren Investigational Site, Huntersville · 13 mi lwen
Study of Safety and Tolerability of BCA101 Monotherapy and in Combination Therapy in Patients With EGFR-driven Advanced Solid Tumors
Ap rekriteFaz 1
- Levine Cancer Institute, Charlotte
Etid Karsinòm selil skuamèz tèt ak kou nan lòt vil
- Houston, TX47 etid
- Los Angeles, CA42 etid
- Boston, MA40 etid
- Nashville, TN39 etid
- New York City, NY39 etid
- St. Louis, MO28 etid
- Arlington, VA26 etid
- Philadelphia, PA26 etid
- Chicago, IL26 etid
- Atlanta, GA24 etid
- San Antonio, TX22 etid
- Pittsburgh, PA22 etid
Lòt etid nan Charlotte
- Kansè (tout kalite)27 etid
- Kansè nan tete22 etid
- Myelom Miltip21 etid
- Kansè Poumon ki pa ti selil19 etid
- Leksemi mieloïd egi16 etid
- Obèsite16 etid
- Sipwa15 etid
- Kansè kolorektal13 etid
- Kansè ovè12 etid
- Ensifizyans kadyak11 etid
- Kansè Metastatik11 etid
- BPCO9 etid
Sous ClinicalTrials.gov, done yo ranmase Oct 6, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.